Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

Understanding your tumor biology is key to finding the right treatment for pancreatic cancer. Identifying mutations, or changes in a [...] READ MORE ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

Anocca has achieved regulatory approval for its first clinical trial, VIDAR-1, a major milestone in the company’s transition ...

CTA approval marks Anocca’s transition to a clinical-stage companyFirst-in-human VIDAR-1 trial begins with the deployment of ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

The KRAS G12C mutation is found in approximately 3% of all colorectal cancer cases and 1% to 2% of pancreatic adenocarcinoma ...

Researchers have identified a range of genetic alterations that may lead to resistance to KRAS G12C inhibitors in patients ...

KRAS G12D and G12V mutations in pancreatic ductal adenocarcinoma are associated with worse outcomes compared to KRAS wild-type. KRAS G12R mutation is linked to more favorable patient outcomes, with ...

Alterome Therapeutics announced that the first patient has been dosed in the Phase 1/1b trial of ALTA3263 in adults with KRAS mutant solid tumors.